23 November 2026 | Monday | News
ACROBiosystems Suzhou GMP Factory Phase II was completed and put into operation. The project comprises a prokaryotic bulk solution production line and a cell bank production line. Currently, the prokaryotic bulk solution production line has successfully completed trial production and multiple batches of GMP product manufacturing. This marks that ACROBiosystems has now achieved end-to-end production and supply capability for GMP-critical core raw materials used in commercial cell and gene therapy manufacturing.
Following the Phase II facility going into operation, ACROBiosystems has further enhanced its independent supply capability for GMP-grade products. In addition to the existing eukaryotic bulk solution production and formulation capabilities across various product types, the company has added prokaryotic bulk solution and GMP-grade cell line production, enabling it to provide global customers with more direct, more comprehensive, more stable, and more efficient product and service support.
Since the Suzhou facility Phase I went into operation in 2024, it has successfully produced nearly 100 high-quality GMP-grade products, including cytokines, antibodies and magnetic beads for cell activation, universal nucleases, Cas enzymes, media and kits. The commissioning of Phase II will further leverage the economies of scale of GMP manufacturing, continuously improving production efficiency and cost advantages.
The vision of ACROBiosystems Suzhou GMP Intelligent Facility is to be a high-quality, flexible, and supply-chain-resilient bio-reagents and materials manufacturing base for the future biopharmaceutical market. Looking ahead, the facility will continue to strengthen its independent production capacity and quality management systems, empowering global biomedical customers to accelerate drug development and commercialization with high-quality, high-reliability critical reagents and solutions.
Most Read
Bio Jobs
News